Method for preparing tamsulosin or medicinal salt thereof by using immobilized catalyst
By using a solid-loaded palladium hydroxide catalyst in a micro reactor for hydrogenation reaction, the synthesis route of tamsolosin is simplified, and the problems of complex and high cost in the synthesis route in the prior art are solved, thus achieving high efficiency and environmental protection industrial production.
Patent Information
- Application Number
- CN202411491084.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing synthesis route of Tamsolosin is complex and costly, with harsh reaction conditions, making it difficult to meet the needs of industrial production and environmental protection requirements.
The continuous flow reaction technology is adopted to carry out hydrogenation reaction in a microreactor using a solid-loaded palladium hydroxide catalyst in a silica to control the flow rate ratio and molar ratio of compound d to hydrogen, adjust the reaction temperature and pressure, simplify the synthesis route and reduce costs.
It realizes efficient synthesis of Tansorosin, simplifies the process flow, reduces costs and environmental pressure, improves the selectivity and handling of reactions, and is suitable for industrial production.
Smart Images

Figure SMS_8 
Figure SMS_10 
Figure QLYQS_1
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing tamsulosin or a pharmaceutically acceptable salt thereof using a solid-supported catalyst. Background Art
[0002] Tamsulosin, a drug developed by Yamanouchi Pharmaceutical for urination disorders caused by prostatic hyperplasia, .
[0003] The synthetic route of tamsulosin mainly uses 5-acetonyl-2-methoxybenzenesulfonamide as the substrate. R -1-phenylethylamine undergoes an "enamine-reduction" step to obtain compound d, and then undergoes metal palladium catalytic hydrogenation and other steps to obtain the target product. .
[0004] Continuous flow reaction has become a new reaction technology and has been successfully used to synthesize a variety of organic compounds. Its reaction device consists of a syringe pump, connecting microtubes, microreactors, detectors, etc. Its advantage is that it significantly increases the area-volume ratio of the fluid environment, resulting in a series of unique effects related to the surface of the object in the microfluidic system, such as laminar flow effect, surface tension, capillary effect, rapid heat conduction effect, etc. Therefore, the use of continuous reactor technology can enhance factors that affect organic synthesis reactions such as mass transfer and heat transfer effects, and can change the flow pattern and mixing program of the substrate by designing channels, regulate the direction and degree of the reaction, and improve the selectivity, speed and control safety of the reaction, which is suitable for industrial production needs.
[0005] To this end, the present invention provides a new synthesis idea and route, the entire synthesis route is short, and the synthesis cost is reduced; at the same time, harsh reaction conditions are avoided, the reaction conditions are simple, the process operability is strong, it is beneficial to its industrial production needs, and the environmental pressure is reduced. Summary of the invention
[0006] The disclosure provides a method for preparing tamsulosin or a pharmaceutically acceptable salt thereof. The method comprises the steps of: injecting a solution containing compound d and hydrogen into a microreactor containing a solid-supported catalyst for hydrogenation, wherein the solid-supported catalyst is selected from palladium hydroxide solid-supported on silicon dioxide, .
[0007] In the continuous flow reactor, the ratio of the flow rate of the solution containing compound d to the flow rate of hydrogen is selected from 1:50 to 1:150, and can be 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:110, 1:120, 1:130, 1:140, 1:150 or a value between any two values. In some embodiments, the ratio of the flow rate of the solution containing compound d to the flow rate of hydrogen is 1:80 to 1:150. In some embodiments, the ratio of the flow rate of the solution containing compound d to the flow rate of hydrogen is 1:80 or 1:100. In some embodiments, the ratio of the flow rate of the solution containing compound d to the flow rate of hydrogen is 1:120.
[0008] Further, in the continuous flow reactor, the molar ratio of compound d to hydrogen is 1:1.5~1:40, and can be 1:1.5, 1:3.5, 1:5.5, 1:7.5, 1:9.5, 1:11.5, 1:13.5, 1:15.5, 1:17.5, 1:19.5, 1:21.5, 1:23.5, 1:25.5, 1:27.5, 1:29.5, 1:31.5, 1:33.5, 1:35.5, 1:37.5, 1:39.5 or a value between any two values. In some embodiments, the solution containing compound d is injected into the microreactor at a flow rate of 0.1-10 ml / min, which can be 0.1 ml / min, 0.2 ml / min, 0.3 ml / min, 0.4 ml / min, 0.5 ml / min, 0.6 ml / min, 0.7 ml / min, 0.8 ml / min, 0.9 ml / min, 1 ml / min, 2 ml / min, 3 ml / min, 4 ml / min, 5 ml / min, 6 ml / min, 7 ml / min, 8 ml / min, 9 ml / min, 10 ml / min or any value between two values. In some embodiments, the solution containing compound d is injected into the microreactor at a flow rate of 0.4-10 ml / min. In some embodiments, the solution containing compound d is injected into the microreactor at a flow rate of 0.5 ml / min.
[0009] In some embodiments, the hydrogen flow rate is selected from 20 to 80 ml / min and can be 20 ml / min, 30 ml / min, 40 ml / min, 50 ml / min, 60 ml / min, 70 ml / min, 80 ml / min or any value between two values. In some embodiments, the hydrogen flow rate is selected from 50 ml / min.
[0010] In some embodiments, the hydrogenation reaction temperature is selected from 25-50°C, and can be 25°C, 30°C, 35°C, 45°C, 50°C, or any value between two values.
[0011] In some embodiments, the solution containing compound d is injected into the microreactor at a flow rate of 0.4-30 ml / min, the hydrogen flow rate is selected from 20-80 ml / min, and the reaction temperature is 25-50°C.
[0012] In some embodiments, the solution containing compound d is injected into the microreactor at a flow rate of 0.5 ml / min, the hydrogen flow rate is selected from 50 ml / min, and the reaction temperature is 25-50°C.
[0013] On the other hand, maintaining the pressure in the microreactor increases the hydrogenation reaction rate, and the reactor pressure can be maintained at 0-10 MPa, i.e., 0-100 atmospheres. In some embodiments, the reactor pressure is maintained at 1-2 MPa, i.e., 10-20 atmospheres, including 1 MPa, 1.1 MPa, 1.2 MPa, 1.3 MPa, 1.4 MPa, 1.5 MPa, 1.6 MPa, 1.7 MPa, 1.8 MPa, 1.9 MPa or 2 MPa.
[0014] On the other hand, in some embodiments, the amount of catalyst used in the hydrogenation reaction is 3-15%, preferably 5-10% by weight of compound d. In some embodiments, the solution used in the hydrogenation reaction is selected from methanol or ethanol.
[0015] In some embodiments, a method for preparing tamsulosin or a pharmaceutically acceptable salt thereof, the method further comprises the steps of reacting compound e with sulfonyl chloride and aqueous ammonia to form compound f, and reacting compound f with o-ethoxyphenoxyethyl bromide to form tamsulosin. For specific operability and reaction conditions, please refer to CN103664974B and EP0380144B, and the relevant contents are introduced herein for illustration.
[0016] Furthermore, the method disclosed herein also includes post-processing operations, such as one or more steps of filtration, extraction, concentration, column chromatography or hand-type separation to obtain a pure target product.
[0017] The pharmaceutically acceptable salts disclosed herein are products of salt formation between a compound and an acid, wherein the acid is selected from, but not limited to, hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, malic acid or oxalic acid.
[0018] Unless otherwise stated, the terms used in this disclosure have the following meanings: The term "to form" in the present disclosure does not specifically mean that the conversion reaction between two substrates is a single step, but can be a single step or multi-step reaction between two substrates. If the intermediate contains an amino protecting group, the intermediate is subjected to a step of deamination of the protecting agent, and then reacts with the corresponding substrate to obtain the corresponding target product.
[0019] The values in this disclosure are instrumental measurements, which have a certain degree of error. Generally speaking, plus or minus 10% is within the reasonable error range. Of course, the context in which the value is used needs to be considered. For example, the particle size of the active ingredient, the value is the error change after measurement does not exceed plus or minus 10%, can be plus or minus 9%, plus or minus 8%, plus or minus 7%, plus or minus 6%, plus or minus 5%, plus or minus 4%, plus or minus 3%, plus or minus 2% or plus or minus 1%, preferably plus or minus 5%.
[0020] The continuous flow reactor includes modules such as a delivery pump and a catalytic reaction tube (microreactor), and can use the fully automatic hydrogenation reactor produced by Ousheng Technology.
[0021] HPLC determination can be performed using an Agilent high performance liquid chromatograph coupled with a Waters Sunfire C18 4.6*250mm 5μ chromatographic column.
[0022] The reagents disclosed herein can be obtained from commercial sources, such as Pd / c. DETAILED DESCRIPTION
[0023] The present disclosure will be described in detail below in conjunction with specific embodiments so that those skilled in the art can have a more comprehensive understanding of the present disclosure. The specific embodiments are only used to illustrate the technical solutions of the present disclosure and do not limit the present disclosure in any way.
[0024] Embodiment 1:
[0025] Compound d (29 g) was dissolved in ethanol (200 mL) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst silica-supported palladium hydroxide (5%) at flow rates of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 40°C, and all the flow was completed in about 450 minutes (HPLC control, wherein the content of compound e was 98.7%, and the content of unreacted compound d was 0%), filtered, concentrated to dryness under reduced pressure to obtain an oily substance, diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 17.25 g of solid (yield 97%).
[0026] Embodiment 2:
[0027] Compound d (10 g) was dissolved in ethanol (80 mL) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst palladium carbon (5%) at a flow rate of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 40°C, and all the flow was completed in about 160 minutes (HPLC control, unreacted compound d content 0%), filtered, concentrated to dryness under reduced pressure to obtain an oily substance, diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 5.64 g of solid (yield 92%).
[0028] Embodiment 3:
[0029] Compound d (10 g) was dissolved in ethanol (100 mL) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst silica-supported palladium hydroxide (5%) at flow rates of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 80°C, and all the flow was completed in about 225 minutes (HPLC control, unreacted compound d content 0%), filtered, concentrated to dryness under reduced pressure to obtain an oily substance, diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 5.39 g of solid (yield 88%).
[0030] Embodiment 4:
[0031] Compound d (10 g) was dissolved in ethanol (100 mL) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst palladium-alumina (5%) at a flow rate of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 40°C, and all the flow was completed in about 225 minutes (HPLC control, the content of unreacted compound d was 25.4%), filtered, and concentrated to dryness under reduced pressure to obtain an oily substance, which was diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 4.47 g of solid (yield 72.5%).
[0032] Embodiment 5:
[0033] Compound d (10 g) was dissolved in ethanol (100 mL) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst palladium-aluminum hydroxide (5%) at a flow rate of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 40°C, and all the flow was completed in about 225 minutes (HPLC control, unreacted compound d content 26.4%), filtered, concentrated to dryness under reduced pressure to obtain an oily substance, diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 4.29 g of solid (yield 70.1%).
[0034] Embodiment 6:
[0035] Compound d (185.6 g) was dissolved in ethanol (1.28 L) solvent for continuous flow reaction; the solution containing compound d and hydrogen were injected into a microreactor containing a solid catalyst silica-supported palladium hydroxide (5%) at flow rates of 0.5 ml / min and 50 ml / min, respectively, the pressure of the microreactor was maintained at 1-2 MPa, the reaction temperature was 40°C, and the entire flow was completed in about 43 hours (HPLC control, wherein the content of compound e was 98.5%, and the content of unreacted compound d was 0%), filtered, concentrated to dryness under reduced pressure to obtain an oily substance, diluted with dichloromethane, washed with brine, dried, and concentrated to obtain 111 g of a solid (yield 97.5%).
Claims
1. A method for preparing tamsulosin or a pharmaceutically acceptable salt thereof, include: The step of injecting a solution containing compound d and hydrogen into a microreactor containing a solid-supported catalyst to carry out a hydrogenation reaction, wherein the solid-supported catalyst is selected from palladium hydroxide solid-supported on silicon dioxide, 。 2. The method according to claim 1, It is characterized in that The flow rate ratio of the solution containing compound d to the flow rate of hydrogen is selected from 1:50 to 1:
150.
3. The method according to claim 1 or 2, It is characterized in that The solution containing compound d is injected into the microreactor at a flow rate of 0.1-10 ml / min.
4. The method according to claim 1 or 2, It is characterized in that The hydrogen flow rate is selected from 20 to 80 ml / min.
5. The method according to claim 1 or 2, It is characterized in that The hydrogenation reaction temperature is selected from 25 to 50°C.
6. The method according to claim 1 or 2, It is characterized in that The solvent used in the hydrogenation reaction is selected from methanol or ethanol.
7. The method according to claim 1, It is characterized in that The method further comprises the steps of reacting compound e with sulfonyl chloride and ammonia water to form compound f, and reacting compound f with o-ethoxyphenoxyethyl bromide to form tamsulosin. 。
Citation Information
Patent Citations
Aryl[a]indole[2,3-g]quinazine compounds, their preparation methods, pharmaceutical compositions and their applications
CN103664974B
Preparation method of R-5-(2-Aminopropyl)-2-methoxybenzenesulfonyl with high optically active purity
CN101037402A
Aryl [a] indole [2,3-g] quinolizine compound as well as preparation method, pharmaceutical composition and application thereof
CN103664974A
Method for preparing stable tamsulosin hydrochloride
CN106478467A
Preparation method of tamsulosin hydrochloride
CN111320559A
